Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 50,417 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose Clear all
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

NCT01118013
View directory record Official record
Conditions
Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, donor lymphocytes, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, reduced-intensity transplant conditioning procedure, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 69 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Lewes, Delaware • Newark, Delaware • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 27, 2026, 7:37 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Fifth Proof-of-Concept Study to Evaluate the Efficacy of NOBO, a Novel Postbiotic, in Controlling Axillary Odor in Healthy Adults

NCT07884760
View directory record Official record
Conditions
Body Odor
Interventions
NOBO postbiotic, Placebo
Other
Lead sponsor
Kingdom
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 4 Interventional Results available

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

NCT00158860
View directory record Official record
Conditions
Herpes Genitalis
Interventions
Valaciclovir, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 27, 2026, 7:37 PM EDT
Not listed Phase 4 Interventional

A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections

NCT04125082
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
Afrezza Inhalant Product
Drug
Lead sponsor
Diabetes and Glandular Disease Clinic
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 27, 2026, 7:37 PM EDT
Terminated Phase 1 Interventional Results available

Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

NCT02981082
View directory record Official record
Conditions
Systemic Sclerosis, Pulmonary; Hypertension
Interventions
Dimethyl Fumarate (DMF), Placebo Oral Tablet
Drug
Lead sponsor
Robert Lafyatis
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 27, 2026, 7:37 PM EDT
Recruiting Phase 3 Interventional

Improvement of Reproductive Function in Men With Spinal Cord Injury (SCI)

NCT05903859
View directory record Official record
Conditions
Infertility, Male
Interventions
Probenecid 500 Milligrams (mg), probenecid 250 Milligrams (mg), Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 27, 2026, 7:37 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effect of a CCK-1R Agonist on Food Intake in Humans

NCT00600743
View directory record Official record
Conditions
Bulimia
Interventions
GSKI181771X (CCK-1R agonist), Instructions to binge eat, Instructions to eat normally, Placebo
Drug · Behavioral
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 27, 2026, 7:37 PM EDT
Terminated Early Phase 1 Interventional

Geisinger Antibiotic Allergy Pilot Program: Assess and Address

NCT05464615
View directory record Official record
Conditions
Penicillin Allergy
Interventions
Amoxicillin
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Danville, Pennsylvania • Lewiston, Pennsylvania • Scranton, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Human Milk Oligosaccharides in Healthy Adults

NCT05516225
View directory record Official record
Conditions
Healthy
Interventions
PBCLN-003
Drug
Lead sponsor
Prolacta Bioscience
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY573636-sodium in Patients With Metastatic Breast Cancer

NCT00992225
View directory record Official record
Conditions
Breast Cancer
Interventions
LY573636-sodium
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Tampa, Florida • Indianapolis, Indiana • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients

NCT02017717
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Nivolumab, Bevacizumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
46
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

NCT01630889
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Renal Disease, Anemia
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
4
States / cities
Riverside, California • Greenbelt, Maryland • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 2 Interventional

Immune Mechanisms of Vitamin D to Reduce Chronic Pain After Burn

NCT05619289
View directory record Official record
Conditions
Burn Injury, Chronic Pain
Interventions
Ergocalciferol, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

NCT02990468
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
BMX-001, Radiation Therapy, Cisplatin
Drug · Radiation
Lead sponsor
BioMimetix JV, LLC
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 27, 2026, 7:37 PM EDT
Not listed Not applicable Interventional

Monitoring and Adjustment of Medication Therapy for Patients With Heart Disease

NCT01427218
View directory record Official record
Conditions
Coronary Heart Disease, Myocardial Infarction
Interventions
Titration of medications, Lifestyle Counseling, Medication Counseling, Usual Care with Medication Reconciliation
Other · Behavioral
Lead sponsor
Middle Tennessee Research Institute
Other
Eligibility
60 Years to 90 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 2 Interventional Results available

Trial of Roflumilast in Asthma Management (TRIM)

NCT03532490
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Roflumilast 500 Mcg Oral Tablet, Placebo oral capsule
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
7
States / cities
Birmingham, Alabama • Tucson, Arizona • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects

NCT04505397
View directory record Official record
Conditions
Healthy
Interventions
SKL24741, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 2 Interventional

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps

NCT06691113
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps
Interventions
Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • Murrieta, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 1 Interventional

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

NCT00968760
View directory record Official record
Conditions
Lymphoma, B-cell Lymphoma
Interventions
Leukapheresis, Stem Cell Transplant, CD19-specific T Cell Infusion, IL-2, Carmustine, Etoposide, Cytarabine, Melphalan
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 27, 2026, 7:37 PM EDT
Recruiting Phase 1 Interventional

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

NCT06613360
View directory record Official record
Conditions
SLE, SLE (Systemic Lupus)
Interventions
CLN-978
Drug
Lead sponsor
Cullinan Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Avondale, Arizona • Tucson, Arizona • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma

NCT02370160
View directory record Official record
Conditions
Refractory B-Lineage Leukemia, Relapsed B-Lineage Leukemia, Refractory B-Lineage Lymphoma, Relapsed B-Lineage Lymphoma
Interventions
DT2219ARL
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults

NCT00079820
View directory record Official record
Conditions
Smallpox
Interventions
ACAM3000 MVA Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 31 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
2
States / cities
Lenexa, Kansas • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 27, 2026, 7:37 PM EDT
Completed No phase listed Observational

Phase I Targeting Dominant Intraprostatic Lesion Using MR Spectroscopy and HDR Brachytherapy

NCT00807820
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 27, 2026, 7:37 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

NCT06578624
View directory record Official record
Conditions
Solid Tumor
Interventions
SA53-OS (phase 1), SA53-OS (phase 2)
Drug
Lead sponsor
Lamassu Bio Inc
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Canton, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 27, 2026, 7:37 PM EDT